• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA to hold meeting on “serious disease” chronic fatigue syndrome

FDA to hold meeting on “serious disease” chronic fatigue syndrome

April 22, 2013
CenterWatch Staff

The FDA will hold a first-ever public workshop on April 25-26, 2013, to discuss how best to facilitate and expedite the development of safe, effective drug therapies to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The workshop is open to pharmaceutical companies, researchers, clinicians and patients, and it will be live-streamed online.

Currently there are no FDA-approved medications for ME/CFS, leaving patients, which number more than 1 million, with no hope for a cure or treatment. Recently, the FDA raised the significance of ME/CFS by declaring it a "serious disease or set of diseases for which there are no approved treatments." This designation, combined with what is now known about the biology of the disease and the opportunities to repurpose existing drugs, gives patients hope that drug companies will take advantage of an expedited drug development and approval process to invest in drugs for ME/CFS.

This meeting will be of interest to pharmaceutical companies that deal with neurological, immunological, viral and autoimmune diseases or with repurposing of existing drugs. Information about the FDA meeting was published in the Federal Register and the Pink Sheet.

ME/CFS is a disabling disease that causes severe dysfunction of neurological, immune, endocrine and energy production systems. Recent studies indicate it may be due to a virus or be an autoimmune disease. ME/CFS is characterized by nonrestorative sleep, cognitive impairments, orthostatic intolerance, debilitating weakness, pain, fever and the hallmark symptom of post-exertional malaise which causes severe relapse upon minimal mental or physical exertion.

For more information on registration click here.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing